|
|
|
|
|
|
|
|
|
|
|
|
|
15.05.25 - 17:03
|
Element Biosciences Welcomes Dr. Madhuri Hegde to its Board of Directors (Business Wire)
|
|
|
SAN DIEGO--(BUSINESS WIRE)--Element Biosciences, Inc., a company democratizing access to advanced life science solutions, today announced that Madhuri Hegde, Ph.D., has joined its board of directors. Dr. Hegde currently serves as senior vice president and Chief Scientific Officer at Revvity, Inc., where she leads the strategic scientific direction of the company. A board-certified diplomate in clinical molecular genetics from the American Board of Medical Genetics and Genomics (ABMGG), Dr. Hegde brings an incredible depth of experience that will shape Element's growth and trajectory.
"Madhuri brings exceptional scientific leadership and a profound understanding of clinical genomics that aligns perfectly with Element's mission," said Molly He, CEO and co-founder of Element Biosciences. "Her extensive experience in translating biological discoveries into practical applications will be invaluable as we continue to innovate and expand access to the highest quality tools for biological research."
"Element Bi...
|
|
|
06.05.25 - 11:18
|
Live Cell Imaging Market Focused Insights Report 2025-2030, Profiling Agilent Technologies, BD, Danaher, PerkinElmer, Merck KgaA, Thermo Fisher Scientific and Zeiss - ResearchAndMarkets.com (Business Wire)
|
|
|
DUBLIN--(BUSINESS WIRE)--The "Live Cell Imaging Market - Focused Insights 2025-2030" report has been added to ResearchAndMarkets.com's offering.
The Live Cell Imaging Market was valued at USD 2.68 billion in 2024, and is projected to reach USD 4.44 billion by 2030, rising at a CAGR of 8.78%.
The global live cell imaging market report consists of exclusive data on 37 vendors. Agilent Technologies, BD, Danaher, PerkinElmer, Merck, Thermo Fisher Scientific, and Zeiss are some of the leading companies that accounted for the highest market share in the global live-cell imaging market. These vendors offer high-class and reliable live-cell imaging equipment, consumables, and software solutions that meet customers' requirements and international regulations.
Leading vendors are increasing the efficiency of their products and strengthening their market position. These companies have a strong brand image and wide geographical reach across the global market. Also, the adoption of various strategies, such...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28.04.25 - 12:06
|
Revvity Announces Financial Results for the First Quarter of 2025 (Business Wire)
|
|
|
Revenue of $665 million; 2% reported growth; 4% organic growth
GAAP EPS of $0.35; Adjusted EPS from continuing operations of $1.01
Reaffirms full year 2025 organic growth and adjusted EPS guidance
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 30, 2025.
The Company reported GAAP earnings per share of $0.35, as compared to $0.21 in the same period a year ago. Revenue for the quarter was $665 million, as compared to $650 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $72 million, as compared to $44 million for the same period a year ago. GAAP operating profit margin from continuing operations was 10.9% as a percentage of revenue, as compared to 6.8% in the same period a year ago.
Adjusted earnings per share from continuing operations for the quarter was $1.01, as compared to $0.98 in the same period a year ago. Adjusted operating income was $170 million, as compared t...
|
|
|
|
|
|
|
24.04.25 - 22:06
|
Revvity Board Declares Quarterly Dividend (Business Wire)
|
|
|
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2025 to all shareholders of record at the close of business on July 18, 2025.
About Revvity
At Revvity, “impossible” is inspiration, and “can't be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in ...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
